Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKDCT080 in GCC-positive Solid Tumors
NCT05875402Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XKDCT080 in solid tumor, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Adverse Events (AE) at 12 months. Status: unknown.
02
Drugs
XKDCT080
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05875402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875402.